Kei Yamashiro

Prof. Kei Yamashiro

Department of Neurosurgery, Fujita Health University Okazaki Medical Center, Okazaki, Japan
+1
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2021 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Open access
PDF file
SHSaeko Higashiguchi
Saeko Higashiguchi
ASAkiyo Sadato
Akiyo Sadato
INIchiro Nakahara
Ichiro Nakahara
SMShoji Matsumoto
Shoji Matsumoto
MHMotoharu Hayakawa
Motoharu Hayakawa
YHYuichi Hirose
Yuichi Hirose
Background Thromboembolic complications (TECs) are frequent during the endovascular treatment of unruptured aneurysms. To prevent TECs, dual antiplatelet therapy using aspirin and clopidogrel is recommended for the perioperative period. In patients with a poor response, clopidogrel is a risk factor for TECs. To prevent TECs, our study assessed the stratified use of prasugrel. Methods Patients who underwent endovascular therapy for unruptured cerebral aneurysms from April 2017 to August 2019 were enrolled in this clinical study and given premedication with aspirin and clopidogrel for 2 weeks prior to the procedure. P2Y12 reaction units (PRU) were measured using the VerifyNow assay on the day before the procedure (tailored group). In subgroups with PRU <240, the clopidogrel dose was maintained (CPG subgroup). In subgroups with PRU ≥240, clopidogrel was changed to prasugrel (PSG subgroup). We compared the occurrence of TECs with retrospective consecutive cases from January 2015 to March 2017 without PRU assessments (non-tailored group). The frequency of TECs within 30 days was assessed as the primary endpoint. Results The tailored and non-tailored groups comprised 167 and 50 patients, respectively. TECs occurred in 11 (6.6%) and 8 (16%) patients in the tailored and non-tailored groups (P=0.048), respectively. The HR for TECs was significantly reduced in the tailored group (HR 0.3, 95% CI 0.11 to 0.81); P=0.017) compared with the non-tailored group. Conclusion The results suggest that tailored dual antiplatelet therapy medication with PRU significantly reduces the frequency of TECs without increasing hemorrhagic complications.

24 February 2021 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
KYKei Yamashiro
Kei Yamashiro
JMJun Muto
Jun Muto
AWAkira Wakako
Akira Wakako
KMKazuhiro Murayama
Kazuhiro Murayama
DKDaijiro Kojima
Daijiro Kojima
YHYuichi Hirose
Yuichi Hirose

4 March 2020 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
KYKei Yamashiro
Kei Yamashiro
KNKazutaka Nakao
Kazutaka Nakao
SOShigeo Ohba
Shigeo Ohba
YHYuichi Hirose
Yuichi Hirose
Background/Aim: Temozolomide (TMZ) induces prolonged arrest of human glioma cells in the G2/M phase and inhibition of the G2 checkpoint intensifies the effect of TMZ. These findings suggest that the G2 checkpoint is linked to DNA repair mechanisms. Materials and Methods: To clarify the mechanism of TMZ resistance, we established TMZ-resistant (TR) clones by serial treatment of U87MG cells with TMZ. We evaluated TMZ-induced cell cycle arrest and the effect of various G2 checkpoint inhibitors. Results: We observed that longer exposure (over 6 months) to TMZ enriched the proportion of TR clones that underwent only minimal G2 arrest following TMZ treatment compared to short exposure (4 months) to TMZ. Expression of MSH6 was reduced in these clones. None of the G2 checkpoint inhibitors could resensitize TR clones to TMZ. Conclusion: Longer drug treatment may induce resistance of cells to DNA damaging agent(s) by means of mismatch repair modification.

24 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
SOShigeo Ohba
Shigeo Ohba
KYKei Yamashiro
Kei Yamashiro
YHYuichi Hirose
Yuichi Hirose
Resistance to temozolomide and intratumoral heterogeneity contribute to the poor prognosis of glioma. The mechanisms of temozolomide resistance can vary within a heterogeneous tumor. Temozolomide adds a methyl group to DNA. The primary cytotoxic lesion, O6-methylguanine, mispairs with thymine, leading to a futile DNA mismatch repair cycle, formation of double-strand breaks, and eventual cell death when O6-methylguanine DNA methyltransferase (MGMT) is absent. N7-methylguanine and N3-methyladenine are repaired by base excision repair (BER). The study aim was to elucidate temozolomide resistance mechanisms and identify methods to overcome temozolomide resistance in glioma. Several temozolomide-resistant clones were analyzed. Increased homologous recombination and mismatch repair system deficiencies contributed to temozolomide resistance. Inhibition of homologous recombination resensitized resistant cells with high homologous recombination efficiency. For the mismatch repair-deficient cells, inhibition of BER by PARP inhibitor potentiated temozolomide-induced cytotoxicity. Dianhydrogalactiol is a bifunctional DNA-targeting agent that forms N7-alkylguanine and inter-strand DNA crosslinks. Dianhydrogalactiol reduced the proliferation of cells independent of MGMT and mismatch repair, inducing DNA double-strand breaks and apoptosis in temozolomide-resistant cells. Further, inhibition of chk1 or homologous recombination enhanced dianhydrogalactiol-induced cytotoxicity in the cells. Selecting treatments most appropriate to the types of resistance mechanisms can potentially improve the prognosis of glioma.

1 September 2018
Verified
Book Chapter
Closed access
PDF file
AFAlberto Feletti
Alberto Feletti
XWXiangdong Wang
Xiangdong Wang
STSandeep Talari
Sandeep Talari
TMTushit Mewada
Tushit Mewada
DMDilshod Mamadaliev
Dilshod Mamadaliev
YKYoko Kato
Yoko Kato

15 September 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
SNShunsuke Nakae
Shunsuke Nakae
TKTakema Kato
Takema Kato
KMKazuhiro Murayama
Kazuhiro Murayama
HSHikaru Sasaki
Hikaru Sasaki
MAMasato Abe
Masato Abe
YHYuichi Hirose
Yuichi Hirose
Most IDH mutant gliomas harbor either 1p/19q co-deletions or TP53 mutation; 1p/19q co-deleted tumors have significantly better prognoses than tumors harboring TP53 mutations. To investigate the clinical factors that contribute to differences in tumor progression of IDH mutant gliomas, we classified recurrent tumor patterns based on MRI and correlated these patterns with their genomic characterization. Accordingly, in IDH mutant gliomas (N = 66), 1p/19 co-deleted gliomas only recurred locally, whereas TP53 mutant gliomas recurred both locally and in remote intracranial regions. In addition, diffuse tensor imaging suggested that remote intracranial recurrence in the astrocytomas, IDH-mutant with TP53 mutations may occur along major fiber bundles. Remotely recurrent tumors resulted in a higher mortality and significantly harbored an 8q gain; astrocytomas with an 8q gain resulted in significantly shorter overall survival than those without an 8q gain. OncoScan® arrays and next-generation sequencing revealed specific 8q regions (i.e., between 8q22 and 8q24) show a high copy number. In conclusion, only tumors with TP53 mutations showed patterns of remote recurrence in IDH mutant gliomas. Furthermore, an 8q gain was significantly associated with remote intracranial recurrence and can be considered a poor prognostic factor in astrocytomas, IDH-mutant.